The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Subgroup classification in DLBCL: barriers and considerations
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, addresses challenges in subgroup classification of patients with diffuse large B-cell lymphoma (DLBCL), with reference to the POLARIX trial (NCT03274492), which found enhanced efficacy of R-CHP in patients classified as activated B-cell (ABC) origin. Highlighting the barriers posed by the costly and time-consuming gene expression profiling, Dr Cliff proposes the Hans classification system as a simpler alternative for patient subgrouping. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
